Which donor should be chosen for hematopoietic stem cell transplantation among unrelated HLA-A, -B, and -DRB1 genomically identical volunteers?

Biology of Blood and Marrow Transplantation

Volumn 10, Issue 2, 2004, Pages 128-134

  Ringd́n, Olle ^a   Schaffer, Marie ^a   Le Blanc, Katarina ^a   Persson, Ulla ^a   Hauzenberger, Dan ^a   Abedi, Mohammad R ^a   Olerup, Olle ^a   Ljungman, Per ^a   Remberger, Mats ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Graft versus host disease; Hematopoietic stem cell transplantation; HLA; Unrelated donors

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HLA A ANTIGEN; HLA B ANTIGEN; HLA DP ANTIGEN; HLA DR ANTIGEN; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; PREDNISONE; PSORALEN; THALIDOMIDE; THYMOCYTE ANTIBODY;

ACUTE DISEASE; ADOLESCENT; ADULT; AGE; ARTICLE; BONE MARROW TRANSPLANTATION; BRAIN LEUKEMIA; CANCER MORTALITY; CANCER SURVIVAL; CHILD; CHRONIC DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOMEGALOVIRUS INFECTION; DISEASE SEVERITY; DONOR; DRUG BLOOD LEVEL; FEMALE; GENOME ANALYSIS; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA MATCHING; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INFANT; LEUKEMIA; LYMPH NODE IRRADIATION; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PATIENT SELECTION; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROGNOSIS; PUVA; RISK ASSESSMENT; RISK FACTOR; SERODIAGNOSIS; SURVIVAL TIME; TREATMENT OUTCOME; VOLUNTEER; WHOLE BODY RADIATION;

ADOLESCENT; ADULT; BONE MARROW TRANSPLANTATION; CHILD; CHILD, PRESCHOOL; FEMALE; GRAFT VS HOST DISEASE; HEMATOLOGIC NEOPLASMS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY; HLA ANTIGENS; HLA-A ANTIGENS; HLA-B ANTIGENS; HLA-DR ANTIGENS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS; TISSUE DONORS;

EID: 0742306040     PISSN: 10838791     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbmt.2003.10.001     Document Type: Article

References (48)

1. Beatty P.G. Hansen J.A. Longton G.M. et al. Marrow transplantation from HLA-matched unrelated donors for treatment of hematologic malignancies Transplantation 51 1991 443-447
2. Hows J.M. Bradley B.A. Gore S. Downie T. Howard M. Gluckman E. Prospective evaluation of unrelated donor bone marrow transplantation. The International Marrow Unrelated Search and Transplant (IMUST) Study Bone Marrow Transplant 12 1993 371-380
3. MacKinnon S. Hows J. Goldman J.M. et al. Bone marrow transplantation for chronic myeloid leukemia: the use of histocompatible unrelated volunteer donors Exp Hematol 18 1990 421-425
4. Anasetti C. Howe C. Petersdorf E.W. Martin P.J. Hansen J.A. Marrow transplants from HLA matched unrelated donors: an NMDP update and the Seattle experience Bone Marrow Transplant 13 1994 693-695
5. Davies S.M. Shu X.O. Blazar B.R. et al. Unrelated donor bone marrow transplantation: influence of HLA A and B incompatibility and outcome Blood 86 1995 1636-1642
6. Ringdén O. Bone marrow transplantation using unrelated donors for haematological malignancies Med Oncol 14 1997 11-22
7. Hansen J.A. Petersdorf E. Martin P.J. Anasetti C. Hematopoietic stem cell transplants from unrelated donors Immunol Rev 157 1997 141-151
8. Byrne J.L. Stainer C. Cull G. et al. The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor bone marrow transplantation for leukemia Bone Marrow Transplant 25 2000 411-417
9. Anasetti C. Petersdorf E.W. Martin P.J. et al. Improving availability and safety of unrelated donor transplants Curr Opin Oncol 12 2000 121-126
10. Petersdorf E.W. Anasetti C. Martin P.J. et al. Tissue typing in support of unrelated hematopoietic cell transplantation Tissue Antigens 61 2003 1-11
11. Petersdorf E.W. Longton G.M. Anasetti C. et al. The significance of HLA-DRB1 matching on clinical outcome after HLA-A, -B, -DR identical unrelated donor marrow transplantation Blood 86 1995 1606-1613
12. Nademanee A. Schmidt G.M. Parker P. et al. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate and prednisone Blood 86 1995 1228-1234
13. Petersdorf E.W. Gooley T.A. Anasetti C. et al. Optimize outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient Blood 92 1998 3515-3520
14. Speiser D. Tiercy J.-M. Rufer N. et al. High resolution HLA matching associated with decreased mortality after unrelated bone marrow transplantation Blood 87 1996 4455-4462
15. Morishima Y. Sasazuki T. Inoko H. et al. The clinical significance of human leukocyte antigen (HLA) allele compatibility in patients receiving a marrow transplant from serologically HLA-A, HLA-B and HLA-DR matched unrelated donors Blood 99 2002 4200-4206
16. Ljungman P. Brand R. Einsele H. et al. Donor CMV serological status and outcome of CMV seropositive recipients after unrelated donor stem cell transplantation; an EBMT Megafile analysis. Blood. In press.
17. Kollman C. Howe C.W.S. Anasetti C. et al. Donor characteristics as risk factors in recipients after transplantation of bone marrow from unrelated donors: the effect of donor age Blood 98 2001 2043-2051
18. Sierra J. Storer B. Hansen J.A. et al. Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose Blood 89 1997 4226-4235
19. Ringdén O. Remberger M. Carlens S. et al. Low incidence of acute graft-versus-host disease, using unrelated HLA-A, -B and -DR compatible donors and conditioning including anti-T-cell antibodies Transplantation 66 1998 620-625
20. Remberger M.Storer B.Ringdén O.Anasetti C.Association between pretransplant thymoglobulin and reduced non-relapse mortality rate after marrow transplantation from unrelated donors Bone Marrow Transplant 29 2002 391-397
21. Gale R.P. Bortin M.M. van Bekkum D.W. et al. Risk factors for acute graft-versus-host disease Br J Haematol 67 1987 397-406
22. Boström L. Ringdén O. Gratama J.W. et al. A role of herpes simplex virus serology for the development of acute graft-versus-host disease Bone Marrow Transplant 5 1990 321-326
23. Deeg H.J. Seidel K. Bruemmer B. Pepe M.S. Appelbaum F.R. Impact of patient weight on non-relapse mortality after marrow transplantation Bone Marrow Transplant 15 1995 461-468
24. Le Blanc K. Ringdén O. Remberger M. A low body mass index is correlated to poor survival after allogeneic stem cell transplantation Haematologica 88 2003 1044-1052
25. Remberger M. Naseh N. Aschan J. et al. G-CSF given after haematopoietic stem cell transplantation using HLA-identical sibling donors is associated to a higher incidence of acute GVHD II-IV Bone Marrow Transplant 32 2003 217-223
26. Olerup O. Zetterquist H. HLA-DR typing by PCR amplification with sequence-specific primers (PCR-SSP) in 2 hours: an alternative to serological DR typing in clinical practice including donor-recipient matching in cadaveric transplantation. Tissue Antigens 39 1992 225-235
27. Schaffer M. Aldener-Cannavá A. Remberger M. Ringdén O. Olerup O. Role of HLA-B, HLA-C and HLA-DPA1 incompatibilities in the outcome of unrelated stem-cell transplantation Tissue Antigens 61 2003 1-8
28. Ringdén O. Remberger M. Runde V. et al. Peripheral blood stem cell (PBSC) transplantation from unrelated donors: a comparison with marrow transplantation Blood 94 1999 455-464
29. Ringdén O. Remberger M. Persson U. et al. Similar incidence of graft-versus-host disease using HLA-A, -B and -DR identical unrelated bone marrow donors as with HLA-identical siblings Bone Marrow Transplant 15 1995 619-625
30. Ringdén O. Ruutu T. Remberger M. et al. A randomized trial comparing busulphan with total body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: a report from the Nordic Bone Marrow Transplantation Group Blood 83 1994 2723-2730
31. Remberger M. Svahn B.-M. Hentschke P. Löfgren C. Ringdén O. Effect on cytokine release and graft-versus-host disease of different anti-T-cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation Bone Marrow Transplant 24 1999 823-830
32. Storb R. Deeg H.J. Whitehead J. et al. Marrow transplantation for leukemia and aplastic anemia: two controlled trials of a combination of methotrexate and cyclosporine v cyclosporine alone or methotrexate alone for prophylaxis of acute graft-v-host disease Transplant Proc 19 1987 2608-2613
33. McSweeney P. Storb R. Mixed chimerism: preclinical studies and clinical applications Biol Blood Marrow Transplant 5 1999 192-203
34. Ringdén O. Deeg H.J. Clinical spectrum of graft-versus-host disease In: Ferrara J.L.M. Deeg H.J. Burakoff S. eds. Graft vs Host Disease Second Edition. 1996 525-559 Marcel Dekker, Inc New York
35. Ringdén O. Båryd I. Gahrton G. et al. Early treatment and prophylaxis of graft-versus-host disease using prednisolone In: Touraine J.L. ed. Bone Marrow Transplantation in Europe Vol 2 1981 171-177 Excerpta Medica Amsterdam Excerpta Medica. Symposium Proceedings
36. Sullivan K.M. Witherspoon R.P. Storb R. et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-versus-host disease Blood 72 1998 555-561
37. Peto R. Pike M.C. Armitage P. et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples Br J Cancer 35 1977 1-39
38. Cox D.R. Regression models and life tables J R Stat Soc B 34 1972 187-220
39. Holler E. Kolb H.J. Möller A. et al. Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation Blood 75 1990 1011-1016
40. Antin J. Ferrara J. Cytokine dysregulation and acute graft-versus-host disease Blood 80 1992 2964-2968
41. Remberger M. Ringdén O. Markling L. TNF alpha levels are increased during bone marrow transplantation conditioning in patients who develop acute GVHD Bone Marrow Transplant 15 1995 99-104
42. Storek J. Gooley T. Siadak M. et al. Allogeneic peripheral blood stem cell transplantation may be associated with a high risk of chronic graft-versus-host disease Blood 90 1997 4705-4709
43. Ringdén O. Labopin M. Bacigalupo A. et al. Transplantation of peripheral blood stem cells as compared with bone marrow from HLA-identical siblings in adult patients with acute myeloid leukemia and acute lymphoblastic leukemia J Clin Oncol 20 2002 4655-4664
44. Ringdén O. Deeg H.J. Clinical spectrum of graft-versus-host disease In: Ferrara J.L.M. Deeg H.J. Burakoff S. eds. Graft vs Host Disease Second Edition. 1996 525-559 Marcel Dekker, Inc New York
45. Varney M.D. Lester S. McCluskey J. Gao X. Tait B.D. Matching for HLA DPA1 and DPB1 alleles in unrelated bone marrow transplantation Hum Immunol 60 1999 532-538
46. Petersdorf E.W. Gooley T. Malkki M. et al. The biological significance of HLA-DP gene variation in haematopoietic cell transplantation Br J Haematol 112 2001 988-994
47. Loiseau P. Espérou H. Busson M. et al. DPB1 disparities contribute to severe GVHD and reduced patient survival after unrelated donor bone marrow transplantation Bone Marrow Transplant 30 2002 497-502
48. Olerup O. Moller E. Persson U. HLA-DP incompatibilities induce significant proliferation in primary mixed lymphocyte cultures in HLA-A, -B, -DR and -DQ compatible individuals: implications for allogeneic bone marrow transplantation Tissue Antigens 36 1990 194-202